BACKGROUND AND PURPOSE: To study a four-point combined analysis (Quadrella) of optimal outcome among patients treated with exclusive permanent seed prostate brachytherapy (PB), as defined by the likelihood of achieving disease control and preserving normal urinary, gastro-intestinal (GI) and sexual function.
MATERIALS AND METHODS: 384 patients with localized prostate cancer underwent PB at our institution with 125I at a dose level of 144Gy. Subjects with erectile dysfunction who did not respond to medication were excluded. 281 patients with minimum 3-year follow-up were evaluated. Patients with concurrent biochemical progression-free survival (bPFS), absent urinary and GI toxicities (grade 0 toxicities according to CTCAE v 3.0) and preserved sexual potency (with our without medication) were classified as the Quadrella group.
RESULTS: Among the 281 patients analyzed, the Quadrella was achieved in 49.1%, 48.0%, 50.4%, 41.7% and 65.2% in years 3-7, respectively. bPFS rates were 82.6-96.1%, corresponding potency rates were 63.6-82.3%, and normal urinary and GI function rates were 64.8-82.6% and 95-100%, respectively. By multivariate analysis, significant predictors of Quadrella were age (p=0.015), baseline IPSS (p=0.03) and time since PB (p=0.02).
CONCLUSION: Urinary and sexual toxicity remained the most common reasons for excluding patients from a perfect outcome (Quadrella), defined by strict criteria. This analysis can be useful for subsequent comparison between treatment modalities.
Written by:
Tétreault-Laflamme A, Zilli T, Meissner A, Larrivée S, Sylvestre MP, Delouya G, Taussky D. Are you the author?
Département de Radio-Oncologie, Centre hospitalier de l'Université de Montréal (CHUM) - Hôpital Notre-Dame, Canada; Centre de recherche, Centre hospitalier de l'Université de Montréal (CRCHUM), Canada; Division of Radiation Oncology, Geneva University Hospital, Switzerland.
Reference: Radiother Oncol. 2014 Feb 20. pii: S0167-8140(14)00033-4.
doi: 10.1016/j.radonc.2014.01.017
PubMed Abstract
PMID: 24560751
UroToday.com Prostate Cancer Section
